Skip to Primary Navigation

Skip to main content

Major generic drug firms pay big fine, divest key lines in agreement with DOJ

DOJ resolves criminal antitrust charges against big pharma, with a novel twist as businesses agree to divest key product lines.

Premium article

Julie DiMauro

Image of a pharmacist stocking shelves with bottles of pills.
Photo: Joe Raedle/Getty Images
Click to share on Facebook (Opens in new window/tab) Click to share on X (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

In the first US Department of Justice (DOJ) resolution to require pharmaceutical companies to divest drug-product lines, the agency announced on Monday two deferred prosecution agreements resolving criminal antitrust charges against Teva Pharmaceuticals USA, Inc. and Glenmark Pharmaceuticals Inc., USA.

The two companies were charged in 2020 with conspiring to

, , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial
Sign in

What’s included:

  • Every new article, plus our 6,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience